Noreen Griffin, the Company’s CEO, said, “This approval is the most important step we have accomplished this year as it launches the last clinical bridging trial before potential market authorization in Nigeria. We believe Lodonal™ will offer meaningful clinical benefit for patients with HIV/AIDS where there continues to be serious unmet medical needs. We believe this is the first step in providing an affordable, easy to administer, immune therapy into emerging nations.”
